DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for young-onset Parkinson disease — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleYoung-onset Parkinson disease maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for young-onset parkinson disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
synaptojanin 1 (SYNJ1) — SYNJ1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7A17 · 2.73 Å · ligand (2R)-3-{[(R)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane
-1,2-diyl dioctanoate (IP9). Experimental structure, not a prediction.
What the evidence adds up to
Early-onset parkinsonism is defined as disease onset before age 40 or 50 years. It is rarer than classical late-onset Parkinson's disease and can overlap with juvenile-onset forms. A correct diagnosis of the specific cause is critical for counselling, family and work planning, and selecting symptomatic or etiopathogenic treatments. Clinical features, radiological and laboratory findings guide the differential diagnosis. The condition can be primary or secondary.
Two types of recessive familial early-onset PD are caused by dysfunction of the PINK1 gene and by mutations in the Parkin gene. These are forms of autosomal recessive juvenile parkinsonism. The genetic basis of Parkinson's disease includes both familial and sporadic cases, and hereditary burden may not be traced in recessive inheritance with low gene penetrance or if the patient dies before disease onset. Next-generation sequencing continues to identify new gene mutations underlying sporadic cases.
A first-person account describes a mother diagnosed with young-onset Parkinson's disease at age 46, after being asked to demonstrate her gait in front of medical students during a teaching session. The author notes that young-onset Parkinson's disease is not common and lists tremor, poverty of movement, and falls among the devastating symptoms.
No clinical trial data, no drug efficacy numbers, no survival or response rates are reported in these abstracts. What is still missing are large-scale, well-funded clinical trials specifically for young-onset populations, validated biomarkers to distinguish the many causes of early-onset parkinsonism, and patient stratification by genetic subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Parkinson s Disease · 2021 · 71 citations · open access
A Practical Approach to Early-Onset Parkinsonism
AbstractEarly-onset parkinsonism (EO parkinsonism), defined as subjects with disease onset before the age of 40 or 50 years, can be the main clinical presentation of a variety of conditions that are important to differentiate. Although rarer than classical late-onset Parkinson's disease (PD) and not infrequently overlapping with forms of juvenile onset PD, a correct diagnosis of the specific cause of EO parkinsonism is critical for offering appropriate counseling to patients, for family and work planning, and to select the most appropriate symptomatic or etiopathogenic treatments. Clinical features, radiological and laboratory findings are crucial for guiding the differential diagnosis. Here we summarize the most important conditions associated with primary and secondary EO parkinsonism. We also proposed a practical approach based on the current literature and expert opinion to help movement disorders specialists and neurologists navigate this complex and challenging landscape.
Uncovering the roles of PINK1 and Parkin in mitophagy
AbstractParkinson disease (PD) is the second most prevalent neurodegenerative disorder, and thus elucidation of the pathogenic mechanism and establishment of a fundamental cure is essential in terms of public welfare. Fortunately, our understanding of the pathogenesis of two types of recessive familial PDs--early-onset familial PD caused by dysfunction of the PTEN induced putative kinase 1 (PINK1) gene and autosomal recessive juvenile Parkinsonism (ARJP) caused by a mutation in the Parkin gene--has evolved and continues to expand.
Movement Disorders · 1993 · 43 citations · open access
Early combination therapy with bromocriptine and levodopa in parkinson's disease
AbstractThe use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a standard of care. This recommendation is based on the theory that LD may accelerate the progression of PD and clinical experience using Br monotherapy in early Parkinson's disease, which suggested that Br causes fewer late complications. This article reviews these arguments and shows that the theories are unproven. A single, uncontrolled trial is often referred to as evidence for efficacy of early combination therapy. We critically review this and five other studies which have evaluated the treatment strategy. We show that the literature is often misleading and that these trials do not support the efficacy of early combination therapy. We conclude that there is no justifiable reason to use a combination of Br and LD in early parkinsonian patients.
Living with Parkinson's disease—a child's perspective
AbstractI was 10 years old when my mother came back from a large London teaching hospital having been given the diagnosis of young onset Parkinson's disease. She was 46 years of age. She had made the diagnosis herself before this appointment. She was first told it by medical students when, during a consultant led teaching session, she had been asked to walk across the front of a lecture theatre to show the characteristic gait. She was humiliated, and I was angry. That was when I decided to become a doctor myself.
Fortunately, young onset Parkinson's disease is not common. Most people are aware of the devastating symptoms—the tremor, the poverty of movement, the falls, …
DOAJ (DOAJ: Directory of Open Access Journals) · 2017 · 2 citations
Генетическая основа болезни Паркинсона
AbstractParkinson's disease (PD) is a multifactorial disease that develops in the presence of both genetic and environmental factors. In recent years, there has been sufficient information on the role of genetic predisposition in the development of not only familial cases, but also sporadic ones. A hereditary burden in PD may not be traced in cases of recessive inheritance with a low gene penetrance, as well as in a patient's death before the onset of the disease. Active introduction of molecular genetic methods, including next generation sequencing, can annually identify new gene mutations that underlie sporadic PD cases. This paper provides an overview of the current literature on the genetic aspects of PD with emphasis on the ethnic characteristics of the disease.
Living with Parkinsons disease - a childs perspective
AbstractI was 10 years old when my mother came back from a large London teaching hospital, having been given the diagnosis of young onset Parkinsons disease. She was 46 years of age. She had made the diagnosis herself before this appointment. She was first told it by medical students when, during a consultant-led teaching session, she had been asked to walk across the front of a lecture theatre to show the characteristic gait. She was humiliated, and I was angry. That was when I decided to become a doctor myself.
Fortunately, young onset Parkinsons disease is …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
